In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, NewAmsterdam Pharma Company NV (NASDAQ: NAMS) closed at $22.56 down -3.63% from its previous closing price of $23.41. In other words, the price has decreased by -$3.63 from its previous closing price. On the day, 1.11 million shares were traded. NAMS stock price reached its highest trading level at $23.34 during the session, while it also had its lowest trading level at $22.05.
Ratios:
For a deeper understanding of NewAmsterdam Pharma Company NV’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.08 and its Current Ratio is at 8.08. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $48.
On March 14, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $35.Scotiabank initiated its Sector Outperform rating on March 14, 2024, with a $35 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 26 ’25 when Michael H. Davidson bought 12,258 shares for $23.41 per share.
Douglas F Kling bought 16,539 shares of NAMS for $387,178 on Mar 26 ’25. On Mar 04 ’25, another insider, Topper James N, who serves as the Director of the company, bought 4,005 shares for $21.02 each. As a result, the insider paid 84,203 and bolstered with 3,012,434 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAMS now has a Market Capitalization of 2570824704 and an Enterprise Value of 1643747840. For the stock, the TTM Price-to-Sale (P/S) ratio is 54.38 while its Price-to-Book (P/B) ratio in mrq is 3.22. Its current Enterprise Value per Revenue stands at 36.076 whereas that against EBITDA is -9.33.
Stock Price History:
The Beta on a monthly basis for NAMS is -0.07, which has changed by 0.031277537 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, NAMS has reached a high of $27.29, while it has fallen to a 52-week low of $15.19. The 50-Day Moving Average of the stock is 3.47%, while the 200-Day Moving Average is calculated to be 12.21%.
Shares Statistics:
For the past three months, NAMS has traded an average of 858.71K shares per day and 1179610 over the past ten days. A total of 108.06M shares are outstanding, with a floating share count of 58.10M. Insiders hold about 47.10% of the company’s shares, while institutions hold 48.02% stake in the company. Shares short for NAMS as of 1741910400 were 4342156 with a Short Ratio of 5.06, compared to 1739491200 on 2911595. Therefore, it implies a Short% of Shares Outstanding of 4342156 and a Short% of Float of 5.9499998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of NewAmsterdam Pharma Company NV (NAMS) is currently being evaluated by 8.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.37 and low estimates of -$0.5.
Analysts are recommending an EPS of between -$1.48 and -$2.01 for the fiscal current year, implying an average EPS of -$1.73. EPS for the following year is -$1.74, with 8.0 analysts recommending between -$1.19 and -$2.16.
